Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 May;18(5):671-9.
doi: 10.1002/j.1532-2149.2013.00415.x. Epub 2013 Oct 29.

Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study

C G Maihöfner  1 , M-L S Heskamp
Affiliations
Randomized Controlled Trial

Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study

C G Maihöfner et al. Eur J Pain. 2014 May.

Abstract

Background: This study evaluates the impact of the duration of pre-existing peripheral neuropathic pain on the therapeutic response to the capsaicin 8% cutaneous patch.

Methods: The non-interventional QUEPP (QUTENZA - safety and effectiveness in peripheral neuropathic pain) study evaluated the effectiveness of Qutenza(TM) in 1044 non-diabetic patients with peripheral neuropathic pain, who received a single application. Follow-up visits were scheduled at weeks 1-2, 4, 8 and 12. A pre-defined co-analysis of changes in average pain intensity was performed based on the duration of pre-existing pain.

Results: In patients with pre-existing pain for <6 months, the mean relative change of the numeric pain rating scale score on days 7-14 to week 12 versus baseline was -36.6% [4.6 standard error of the mean (SEM); n = 105], -25.1% (1.9 SEM; n = 311) in patients with pain duration of 6 months to 2 years, -22.3% (1.6 SEM; n = 391) in patients with pain for >2-10 years, and -19.2% (2.6 SEM; n = 99) in patients with pain for >10 years. Thirty percent and 50% responder rates were 61.7% and 39.3% in patients with pre-existing pain for <6 months, 42.3% and 23.3% in patients with pain for 6 months to 2 years, 40.9% and 21.6% in patients with pain for >2-10 years, and 32.3% and 14.1% in patients with pain for >10 years.

Conclusions: The highest treatment response to the capsaicin 8% cutaneous patch was observed in patients with a history of pre-existing peripheral neuropathic pain of less than 6 months, suggesting that early initiation of topical treatment might be indicated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time course of mean pain intensities in the subgroups of duration of pre-existing peripheral neuropathic pain (m, months; y, years, NPRS, numeric pain rating scale 0–10; **p ≤ 0.01; ***p ≤ 0.001, single t-test).
Figure 2
Figure 2
Mean relative changes (%) of short form-12 (SF-12) physical and mental summary scale scores between week 12 and baseline in subgroups of duration of pre-existing pain (m, months; y, years).
Figure 3
Figure 3
Percentage of patients with co-medication for neuropathic pain in the subgroups of pre-existing duration of pain (m, months; y, years; NP, neuropathic pain).
See this image and copyright information in PMC

References

    1. Backonja MM, Irving G, Webster L, Tobias J, Vanhove G. Efficacy of NGX-4010, a prescription strength capsaicin 8% patch for the treatment of postherpetic neuralgia, across a range of patient populations. Neurology. 2011;76(9, S4):A110.
    1. Brown S, Simpson DM, Moyle G, Brew B, Schifitto G, Larbalestier N, Orkin C, Fisher M, Vanhove GF, Tobias JK. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: Integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther. 2013;10:5. - PMC - PubMed
    1. Burgmer M, Pfleiderer B, Maihofner C, Gaubitz M, Wessolleck E, Heuft G, Pogatzki-Zahn E. Cerebral mechanisms of experimental hyperalgesia in fibromyalgia. Eur J Pain. 2012;16:636–647. - PubMed
    1. Cochrane-Glossar. 2013. Das Deutsche Cochrane Zentrum. Available at: http://www.cochrane.de/de/cochrane-glossar (Accessed 14 June 2013)
    1. Deumens R, Steyaert A, Forget P, Schubert M, Lavand’homme P, Hermans E, De Kock M. Prevention of chronic postoperative pain: Cellular, molecular, and clinical insights for mechanism-based treatment approaches. Prog Neurobiol. 2013;104:1–37. - PubMed

Publication types